Mangalam Drugs & Organics Ltd. (IN:MANGALAM)
:MANGALAM
Want to see IN:MANGALAM full AI Analyst Report?
MANGALAM Stock Chart & Stats
₹30.40
-₹1.02(-0.89%)
At close: 4:00 PM EST
₹30.40
-₹1.02(-0.89%)
Day’s Range― - ―
52-Week Range₹22.70 - ₹94.80
Previous CloseN/A
Volume15.57K
Average Volume (3M)5.11K
Market Cap
₹440.03M
Enterprise Value₹1.36B
Total Cash (Recent Filing)₹96.75M
Total Debt (Recent Filing)₹949.21M
Price to Earnings (P/E)―
Beta0.79
Next Earnings
May 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-6.21
Shares Outstanding15,828,248
10 Day Avg. Volume11,101
30 Day Avg. Volume5,111
Financial Highlights & Ratios
PEG Ratio-0.11
Price to Book (P/B)0.84
Price to Sales (P/S)0.39
P/FCF Ratio5.56
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Specialty Chemicals & API B2B ModelMangalam's core business is manufacturing specialty chemicals and APIs for B2B customers. This model benefits from recurring procurement, higher switching costs related to quality/compliance, and structural demand from pharma and chemical supply chains, supporting stable midterm revenue visibility.
Manageable Leverage And Stable EquityThe balance sheet reflects a balanced position with manageable leverage and consistent shareholders' equity. That financial stability gives the company flexibility to absorb cyclical downturns, fund working capital, and access financing at reasonable terms, reducing insolvency risk over the medium term.
Improved Operating Cash GenerationOperating cash flow improvement signals stronger cash conversion from operations, enhancing ability to cover short-term obligations, support capex and maintain operations without immediate external funding. Sustained OCF underpins medium-term resilience despite FCF variability.
Bears Say
Declining Revenue And Contracting MarginsRecent declines in revenue and net income, and contracting EBIT/EBITDA margins, weaken scale economics and reduce reinvestment capacity. If structural or product-mix issues persist, profitability pressure can erode competitive position, constrain R&D/capex and increase sensitivity to input cost swings.
Inconsistent Free Cash FlowNegative or uneven free cash flow in several periods limits the company's ability to self-fund growth, deleverage or return capital. Over a multi-quarter horizon this raises reliance on external financing for investments and increases execution risk if revenues remain weak or capex needs rise.
Rising Total Debt TrendAn increasing total debt trend, even from manageable leverage, becomes problematic when revenue is falling. Persistently higher debt elevates interest and refinancing risk, compresses financial flexibility and could force concessions on investment or pricing if margins do not recover.
Mangalam Drugs & Organics Ltd. News
MANGALAM FAQ
What was Mangalam Drugs & Organics Ltd.’s price range in the past 12 months?
Mangalam Drugs & Organics Ltd. lowest stock price was ₹22.70 and its highest was ₹94.80 in the past 12 months.
What is Mangalam Drugs & Organics Ltd.’s market cap?
Mangalam Drugs & Organics Ltd.’s market cap is ₹440.03M.
When is Mangalam Drugs & Organics Ltd.’s upcoming earnings report date?
Mangalam Drugs & Organics Ltd.’s upcoming earnings report date is May 27, 2026 which is in 28 days.
How were Mangalam Drugs & Organics Ltd.’s earnings last quarter?
Mangalam Drugs & Organics Ltd. released its earnings results on Jan 15, 2026. The company reported -₹6.214 earnings per share for the quarter, missing the consensus estimate of N/A by -₹6.214.
Is Mangalam Drugs & Organics Ltd. overvalued?
According to Wall Street analysts Mangalam Drugs & Organics Ltd.’s price is currently Overvalued.
Does Mangalam Drugs & Organics Ltd. pay dividends?
Mangalam Drugs & Organics Ltd. pays a Notavailable dividend of ₹0.5 which represents an annual dividend yield of N/A. See more information on Mangalam Drugs & Organics Ltd. dividends here
What is Mangalam Drugs & Organics Ltd.’s EPS estimate?
Mangalam Drugs & Organics Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Mangalam Drugs & Organics Ltd. have?
Mangalam Drugs & Organics Ltd. has 15,828,248 shares outstanding.
What happened to Mangalam Drugs & Organics Ltd.’s price movement after its last earnings report?
Mangalam Drugs & Organics Ltd. reported an EPS of -₹6.214 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Mangalam Drugs & Organics Ltd.?
Currently, no hedge funds are holding shares in IN:MANGALAM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Mangalam Drugs & Organics Ltd.
Mangalam Drugs & Organics Limited manufactures and sells drugs, medicines, and allied products in India and internationally. It offers a range of active pharmaceutical ingredients, intermediates, and specialty chemicals, as well as impurities for use in anti-malarial, analgesic/anti-inflammatory, anti-hypertensive, and anti-retroviral applications. The company was incorporated in 1972 and is based in Mumbai, India.
Technical Analysis
Biofil Chemicals & Pharmaceuticals Ltd.
―
Lasa Supergenerics Ltd.
―
Par Drugs and Chemicals Limited
―
Vaishali Pharma Ltd.
―
Vivimed Labs Limited
―